Celebrating 25 Years of Scoop
Special: Up To 25% Off Scoop Pro Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Transgenic cow programme targets lysosomal disease


Transgenic cows programme to target rare lysosomal disease

AgResearch's transgenic cows programme will start work to produce a therapeutic protein to treat the rare lysosomal storage disease Pompe disease, as soon as issues like intellectual property are sorted out. Their decision has won praise from the patient advocacy group, Lysosomal Diseases New Zealand, but concern has already been expressed by LDNZ that continued opposition from MadGE and other anti-GE groups could add further impediments.

Paul Atkinson, Science General Manager at AgResearch announced the addition of Pompe to their target list, at a conference of families and professionals convened in Auckland over the past weekend by LDNZ. The protein for Pompe disease will be one of four to be developed in the project recently approved by ERMA. The conference included one person affected by Pompe disease, among the more than 90 family members and professionals attending LDNZ's first ever conference.

Pompe disease results from an enzyme deficiency in the cells of the patient and this causes lysosomal storage of Glycogen in the muscles of affected patients. "The consequences of this are very severe and newborn babies with this disease die from respiratory problems or heart failure before reaching one year old", said John Forman, Chairperson of LDNZ and Executive Director of NZORD, the New Zealand Organisation for Rare Disorders.

"Pompe also has serious impacts on the health of children with the juvenile form and they are often respirator and wheelchair dependent in their teenage years. Adults have their mobility impaired by the disease and usually need CPAP respirator assistance when sleeping", said Mr Forman, "but treatment of this complex disease is now possible and a completely normal life should occur for future patients, thanks to advances in genetic modification technology".

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

The first trial of a genetically modified enzyme replacement therapy occurred in Holland a few years ago when protein was extracted from the milk of transgenic rabbits and successfully treated several small babies with Pompe disease. "This was the important proof of principle that was needed, and evidence that genetic modification was a necessary part of the process to produce the complex enzyme. The storage was cleared from the muscles and a seriously ill and disabled child returned to normal health", said Mr Forman.

Normal chemical drug production could not make a suitable therapeutic drug, but the transgenic rabbit project had limitations in providing enough protein to treat larger numbers of patients. The company that is continuing the production effort, Genzyme Corporation, is producing the enzyme replacement therapy by large scale fermentation of genetically modified Chinese Hamster Ovary cell lines in huge industrial plants, but this method has its own limitations. It has environmental considerations regarding disposal of large quantities of culture medium used in the production process, and it is also extremely expensive.

"Transgenics offers good therapeutic efficiency but much better cost effectiveness, and it is vital that both these issues are factored in", said Mr Forman. "We already have a scenario where another of the complex Lysosomal proteins has just now been made available for the treatment of Fabry disease, but the CHO cell production process means it is extremely expensive at about $250,000 per patient per year.

"Transgenic cows offer one of the best prospects for getting the right protein structures in the enzyme to make them effective in treating the patient, and at the same time producing them at a cost that should ensure availability to all patients in the world", said Mr Forman.

LDNZ hope that groups like MadGE will not make any further attempts to impede the AgResearch transgenic cows programme. "I wish they could understand that without these innovative experiments in production methods, effective and affordable treatments will not be available to patients", said Mr Forman. "If they do manage to stop the project, it will mean that instead of Pompe disease killing newborn babies and affected children and adults in the future, it will be the actions of ill-informed opponents like MadGE that will be responsible for the deaths by the halt they put on the technology".


© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.